



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

October 2015





© 2015 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.682.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

October 2015

N = 6968



Health Authority	Male	Female	All
FRASER	1297	380	1677
INTERIOR	357	93	450
NORTHERN	135	77	212
VANCOUVER COASTAL	3348	449	3797
VANCOUVER ISLAND	642	152	794
	5779	1151	6930
		Unknown/not stated:	38
		Total:	6968

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2010 - October 2015)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2010 - October 2015)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (October 2010 - October 2015)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (October 2010 - October 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (October 2010 - October 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (October 2010 - October 2015)






1.8 Active and Inactive Participants (October 2010 - October 2015)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (October 2010 - October 2015)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (October 2010 - October 2015)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(October 2010 - October 2015)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (October 2010 - October 2015)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(October 2010 - October 2015)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (October 2010 - October 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(October 2010 - October 2015)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (October 2010 - October 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(October 2010 - October 2015)






1.18 Baseline CD4 for Antiretroviral First Starts
(October 2010 - October 2015)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(October 2010 - October 2015)**






1.20 Cumulative Resistance Testing Results by Resistance Category (October 2010 - October 2015)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (October 2010 - October 2015)





2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	650	5	<40	3
1988	23	8	0	8	8	565	8	<40	3
1989	22	57	2	59	52	530	54	<40	3
1990	21	62	1	63	58	530	62	<40	3
1991	21	39	3	42	37	590	41	<40	3
1992	21	68	6	74	59	550	73	<40	3
1993	20	149	15	164	148	570	161	<40	3
1994	19	96	12	108	88	545	103	<40	3
1995	19	128	23	151	120	540	139	<40	3
1996	17	376	62	438	383	590	430	<40	3
1997	15	312	41	353	310	590	339	<40	3
1998	14	223	49	272	219	550	256	<40	3
1999	14	186	43	229	188	560	219	<40	3
2000	15	140	37	177	152	580	171	<40	3
2001	14	133	36	169	139	550	164	<40	3
2002	13	141	32	173	139	580	162	<40	3
2003	12	177	37	214	181	590	205	<40	3
2004	11	179	48	227	191	570	219	<40	3
2005	10	213	52	265	220	580	253	<40	3
2006	9	220	48	268	217	530	251	<40	3
2007	8	283	55	338	279	590	323	<40	3
2008	7	319	70	389	317	610	368	<40	3
2009	6	347	78	425	363	630	405	<40	3
2010	5	317	75	392	330	650	366	<40	3
2011	4	367	79	446	379	620	419	<40	3
2012	3	314	70	384	320	655	364	<40	3
2013	2	310	71	381	312	590	362	<40	3
2014	1	321	62	383	324	651	370	<40	3
2015	0	313	48	361	328	530	354	<40	3
Total:		5803	1155	6958					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	782	2429	<40	2151	560
FEB-2014	6570	781	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1874	560
MAY-2014	6677	768	2120	<40	1887	560
JUN-2014	6644	783	1994	<40	1768	550
JUL-2014	6682	778	2179	<40	1930	550
AUG-2014	6702	774	2026	<40	1806	570
SEP-2014	6730	770	2284	<40	2005	550
OCT-2014	6760	761	2250	<40	1958	570
NOV-2014	6758	758	1920	<40	1706	580
DEC-2014	6769	765	1896	<40	1689	580
JAN-2015	6743	760	2429	<40	2112	580
FEB-2015	6792	754	1978	<40	1729	570
MAR-2015	6837	748	2173	<40	1896	570
APR-2015	6850	740	2149	<40	1904	580
MAY-2015	6890	739	2032	<40	1786	560
JUN-2015	6905	740	2255	<40	1949	580
JUL-2015	6931	739	2039	<40	1788	580
AUG-2015	6929	753	2076	<40	1753	580
SEP-2015	6937	748	2270	<40	1904	580
OCT-2015	6968	738	2105	<40	1715	590

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1410	2265	100	6683	76	285
FEB-2014	1431	2152	73	496	67	490
MAR-2014	1433	2169	114	3726	99	340
APR-2014	1443	2144	112	128	90	400
MAY-2014	1414	2308	90	617	76	350
JUN-2014	1467	2052	96	423	82	380
JUL-2014	1459	2111	95	982	76	355
AUG-2014	1452	2158	87	208	72	365
SEP-2014	1451	2180	103	866	89	390
OCT-2014	1439	2250	84	257	62	395
NOV-2014	1452	2234	74	3945	64	400
DEC-2014	1474	2172	93	557	72	340
JAN-2015	1512	2044	105	1364	85	310
FEB-2015	1495	2119	101	78	86	380
MAR-2015	1469	2263	101	56	91	410
APR-2015	1474	2262	83	2239	66	475
MAY-2015	1456	2372	73	148	60	430
JUN-2015	1473	2305	95	97	89	430
JUL-2015	1466	2354	70	768	53	380
AUG-2015	1478	2313	82	3244	74	425
SEP-2015	1496	2282	87	128	75	345
OCT-2015	1485	2356	74	<40	57	380

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1410	2	30	144	136	35	11493
FEB-2014	6548	1431	9	40	139	159	9	11537
MAR-2014	6573	1433	9	36	151	146	25	11581
APR-2014	6587	1443	5	27	159	161	14	11617
MAY-2014	6646	1414	14	38	191	152	59	11667
JUN-2014	6618	1467	7	24	142	183	-28	11705
JUL-2014	6659	1459	8	34	176	159	41	11749
AUG-2014	6682	1452	6	18	165	150	23	11781
SEP-2014	6713	1451	2	25	168	158	31	11820
OCT-2014	6738	1439	7	21	159	146	25	11847
NOV-2014	6732	1452	12	19	135	144	-6	11871
DEC-2014	6744	1474	7	39	136	150	12	11920
JAN-2015	6710	1512	13	24	149	187	-34	11955
FEB-2015	6761	1495	7	36	187	162	51	12007
MAR-2015	6812	1469	7	29	174	143	51	12047
APR-2015	6812	1474	15	28	169	172	0	12083
MAY-2015	6853	1456	9	33	171	148	41	12124
JUN-2015	6876	1473	5	36	155	161	23	12171
JUL-2015	6912	1466	5	25	165	147	36	12209
AUG-2015	6912	1478	7	20	145	157	0	12240
SEP-2015	6919	1496	8	34	158	175	7	12283
OCT-2015	6958	1485	1	25	171	152	39	12320

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	6557	0.72%	91.89%	6.31%	1.08%	100.00%
FEB-2014	50	6034	418	68	6570	0.76%	91.84%	6.36%	1.04%	100.00%
MAR-2014	50	6054	424	70	6598	0.76%	91.76%	6.43%	1.06%	100.00%
APR-2014	46	6067	422	76	6611	0.70%	91.77%	6.38%	1.15%	100.00%
MAY-2014	47	6138	418	74	6677	0.70%	91.93%	6.26%	1.11%	100.00%
JUN-2014	50	6107	416	71	6644	0.75%	91.92%	6.26%	1.07%	100.00%
JUL-2014	47	6147	415	73	6682	0.70%	91.99%	6.21%	1.09%	100.00%
AUG-2014	47	6170	414	72	6703	0.70%	92.05%	6.18%	1.07%	100.00%
SEP-2014	50	6185	424	71	6730	0.74%	91.90%	6.30%	1.05%	100.00%
OCT-2014	47	6206	434	73	6760	0.70%	91.80%	6.42%	1.08%	100.00%
NOV-2014	50	6214	424	70	6758	0.74%	91.95%	6.27%	1.04%	100.00%
DEC-2014	45	6229	421	74	6769	0.66%	92.02%	6.22%	1.09%	100.00%
JAN-2015	47	6182	440	74	6743	0.70%	91.68%	6.53%	1.10%	100.00%
FEB-2015	47	6221	451	73	6792	0.69%	91.59%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	46	6302	435	67	6850	0.67%	92.00%	6.35%	0.98%	100.00%
MAY-2015	47	6344	431	68	6890	0.68%	92.08%	6.26%	0.99%	100.00%
JUN-2015	49	6337	447	72	6905	0.71%	91.77%	6.47%	1.04%	100.00%
JUL-2015	46	6364	454	67	6931	0.66%	91.82%	6.55%	0.97%	100.00%
AUG-2015	48	6365	446	70	6929	0.69%	91.86%	6.44%	1.01%	100.00%
SEP-2015	47	6384	442	64	6937	0.68%	92.03%	6.37%	0.92%	100.00%
OCT-2015	49	6413	442	64	6968	0.70%	92.04%	6.34%	0.92%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3862 61%	36 86%	4269 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2430 38%	9 24%	2062 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3912 60%	24 77%	4286 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2545 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3905 60%	17 63%	4286 65%
NOV-2014	6 25%	2547 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3895 59%	19 79%	4268 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3873 59%	37 76%	4245 65%
JAN-2015	10 29%	2584 40%	10 29%	2221 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3848 59%	25 71%	4212 64%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3883 59%	44 85%	4246 64%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3916 59%	30 75%	4272 64%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3917 59%	24 69%	4273 64%
MAY-2015	8 20%	2640 40%	7 18%	2282 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3931 59%	33 83%	4285 64%
JUN-2015	10 21%	2636 39%	10 21%	2290 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3948 59%	37 79%	4299 64%
JUL-2015	4 11%	2660 40%	4 11%	2314 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3950 59%	34 89%	4300 64%
AUG-2015	13 42%	2678 40%	12 39%	2337 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 58%	3945 59%	18 58%	4285 64%
SEP-2015	17 40%	2721 40%	15 35%	2378 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	26 60%	3920 58%	26 60%	4261 63%
OCT-2015	11 30%	2753 41%	10 27%	2409 36%	0 0%	103 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3911 58%	27 73%	4250 63%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2132 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2106 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2074 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	932 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2031 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	971 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 33%	2026 60%	14 67%	990 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2003 59%	6 38%	1020 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1969 58%	10 56%	1037 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1961 58%	11 79%	1051 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1947 58%	7 64%	1057 31%	3 27%	346 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 24%	1916 57%	12 71%	1065 32%	1 6%	339 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1902 57%	10 63%	1092 33%	1 6%	332 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1189 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	254 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	874 35%	0 0%	256 10%
OCT-2015	2 50%	1086 43%	0 0%	312 12%	1 25%	867 34%	1 25%	251 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	76 5%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	252 17%	0 0%	74 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	267 18%	0 0%	74 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	335 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	349 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	355 19%	0 0%	74 4%	2 8%	880 48%	0 0%	1 0%
MAR-2015	9 50%	600 32%	5 28%	367 20%	0 0%	69 4%	4 22%	869 47%	0 0%	2 0%
APR-2015	7 50%	628 33%	4 29%	373 20%	2 14%	67 4%	1 7%	862 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	382 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	712 35%	8 30%	396 20%	0 0%	72 4%	4 15%	875 43%	0 0%	1 0%
JUL-2015	11 58%	748 37%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	12 71%	785 38%	4 24%	413 20%	0 0%	70 3%	1 6%	855 41%	0 0%	1 0%
SEP-2015	17 81%	851 40%	2 10%	414 19%	0 0%	65 3%	2 10%	858 40%	0 0%	1 0%
OCT-2015	14 70%	891 40%	6 30%	437 20%	0 0%	65 3%	0 0%	850 39%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2417	35.75	2190	32.40	1008	14.91	192	2.84	73	1.08	880	13.02
NOV-2014	2419	35.79	2159	31.95	1056	15.63	184	2.72	70	1.04	870	12.87
DEC-2014	2398	35.43	2144	31.67	1103	16.29	185	2.73	74	1.09	865	12.78
JAN-2015	2348	34.82	2124	31.50	1137	16.86	179	2.65	74	1.10	881	13.07
FEB-2015	2364	34.81	2111	31.08	1176	17.31	178	2.62	73	1.07	890	13.10
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2392	34.92	2095	30.58	1239	18.09	184	2.69	67	0.98	873	12.74
MAY-2015	2399	34.82	2094	30.39	1277	18.53	179	2.60	68	0.99	873	12.67
JUN-2015	2369	34.31	2078	30.09	1324	19.17	171	2.48	72	1.04	891	12.90
JUL-2015	2375	34.27	2068	29.84	1353	19.52	170	2.45	67	0.97	898	12.96
AUG-2015	2369	34.19	2044	29.50	1384	19.97	167	2.41	70	1.01	895	12.92
SEP-2015	2330	33.59	2033	29.31	1451	20.92	167	2.41	64	0.92	892	12.86
OCT-2015	2334	33.50	2007	28.80	1494	21.44	167	2.40	64	0.92	902	12.94

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	20	2	3	4	2	8	460
SEP-2015	34	8	1	5	3	15	451
OCT-2015	25	5	2	3	4	9	430

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10027	2578
FEB-2014	10049	2571
MAR-2014	10062	2557
APR-2014	10092	2560
MAY-2014	10116	2554
JUN-2014	10151	2564
JUL-2014	10163	2552
AUG-2014	10212	2586
SEP-2014	10254	2596
OCT-2014	10276	2604
NOV-2014	10307	2626
DEC-2014	10348	2630
JAN-2015	10390	2660
FEB-2015	10436	2667
MAR-2015	10475	2676
APR-2015	10495	2688
MAY-2015	10549	2712
JUN-2015	10635	2759
JUL-2015	10704	2807
AUG-2015	10772	2863
SEP-2015	10861	2918
OCT-2015	10938	2968

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
October 2015

N = 6968

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	13	15	8
	50+	20	30	14
	Total HSDA:	33	45	22
KOOTENAY BOUNDARY	0-19	1	1	0
	20-34	4	4	3
	35-49	18	24	14
	50+	46	61	36
	Total HSDA:	69	90	53
OKANAGAN	0-19	4	4	2
	20-34	22	23	18
	35-49	93	107	69
	50+	194	278	151
	Total HSDA:	313	412	240
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	17	17	14
	35-49	55	69	44
	50+	91	130	76
	Total HSDA:	169	222	135
Total HA:		584	769	450

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	3
	20-34	43	44	35
	35-49	179	215	135
	50+	351	499	277
Total HA:		584	769	450

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	454	610	357
Female	130	159	93

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	450	52	570	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	7	5
	<5 years	10	7
	Total HSDA:	33	22
KOOTENAY BOUNDARY	10 years or more	32	22
	5 years or more	19	15
	<5 years	18	16
	Total HSDA:	69	53
OKANAGAN	10 years or more	169	118
	5 years or more	74	61
	<5 years	70	61
	Total HSDA:	313	240
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	86	61
	5 years or more	36	35
	<5 years	47	39
	Total HSDA:	169	135
Total HA:		584	450

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	303	211
	5 years or more	136	116
	<5 years	145	123
Total HA:		584	450

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	35	49	13	22
KOOTENAY BOUNDARY	59	108	24	41
OKANAGAN	190	647	70	228
THOMPSON/CARIBOO/SHUSWAP	123	406	43	102
Total:	407	1210	150	393

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	12
OKANAGAN	42
THOMPSON/CARIBOO/SHUSWAP	37
Total:	92

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	23	24	18
	35-49	118	129	90
	50+	166	226	134
	Total HSDA:	314	386	248
FRASER NORTH	0-19	20	20	5
	20-34	111	112	93
	35-49	358	409	263
	50+	447	696	367
	Total HSDA:	936	1237	728
FRASER SOUTH	0-19	11	11	5
	20-34	96	98	72
	35-49	357	406	292
	50+	404	601	332
	Unknown	0	1	0
	Total HSDA:	868	1117	701
Total HA:		2118	2740	1677

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	38	38	16
	20-34	230	234	183
	35-49	833	944	645
	50+	1017	1523	833
	Unknown	0	1	0
Total HA:		2118	2740	1677

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1601	2101	1297
Female	517	639	380

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1677	49	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	145	109
	5 years or more	87	68
	<5 years	82	71
	Total HSDA:	314	248
FRASER NORTH	10 years or more	448	330
	5 years or more	234	185
	<5 years	254	213
	Total HSDA:	936	728
FRASER SOUTH	10 years or more	392	307
	5 years or more	237	195
	<5 years	239	199
	Total HSDA:	868	701
Total HA:		2118	1677

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	985	746
	5 years or more	558	448
	<5 years	575	483
Total HA:		2118	1677

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	126	394	44	76
FRASER NORTH	224	1370	62	273
FRASER SOUTH	202	1157	52	343
Total:	552	2921	158	692

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	183
FRASER NORTH	620
FRASER SOUTH	487
Total:	1290

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	21	21	20
	35-49	86	100	70
	50+	194	313	167
	Total HSDA:	303	436	257
RICHMOND	0-19	7	7	1
	20-34	21	21	18
	35-49	45	48	37
	50+	75	114	62
	Total HSDA:	148	190	118
VANCOUVER	0-19	56	59	7
	20-34	411	419	322
	35-49	1606	1881	1214
	50+	2377	3925	1879
	Total HSDA:	4450	6284	3422
Total HA:		4901	6910	3797

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	65	68	8
	20-34	453	461	360
	35-49	1737	2029	1321
	50+	2646	4352	2108
Total HA:		4901	6910	3797

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4311	6077	3348
Female	588	831	449

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3797	51	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	168	138
	5 years or more	53	46
	<5 years	82	73
	Total HSDA:	303	257
RICHMOND	10 years or more	68	50
	5 years or more	37	29
	<5 years	43	39
	Total HSDA:	148	118
VANCOUVER	10 years or more	2214	1598
	5 years or more	1091	858
	<5 years	1145	966
	Never on ART	0	0
	Total HSDA:	4450	3422
Total HA:	4901	3797	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2450	1786
5 years or more	1181	933
<5 years	1270	1078
Never on ART	0	0
Total HA:	4901	3797

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	137	362	54	92
RICHMOND	41	256	13	87
VANCOUVER	527	9718	206	5226
Total:	705	10336	273	5405

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	1
VANCOUVER	98
Total:	105

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	24	26	18
	35-49	81	95	68
	50+	155	247	126
	Total HSDA:		262	370
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	14	15	8
	35-49	33	38	28
	50+	58	86	46
	Total HSDA:		107	141
SOUTH VANCOUVER ISLAND	0-19	9	9	2
	20-34	42	44	29
	35-49	214	252	168
	50+	379	590	299
	Total HSDA:		644	895
Total HA:		1013	1406	794

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	4
	20-34	80	85	55
	35-49	328	385	264
	50+	592	923	471
Total HA:		1013	1406	794

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	812	1132	642
Female	201	274	152

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	794	52	480	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	126	99
	5 years or more	66	57
	<5 years	70	57
	Total HSDA:	262	213
NORTH VANCOUVER ISLAND	10 years or more	48	37
	5 years or more	25	18
	<5 years	34	28
	Total HSDA:	107	83
SOUTH VANCOUVER ISLAND	10 years or more	314	224
	5 years or more	165	133
	<5 years	165	141
	Total HSDA:	644	498
Total HA:		1013	794

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	488	360
5 years or more	256	208
<5 years	269	226
Total HA:	1013	794

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	543	80	180
NORTH VANCOUVER ISLAND	113	232	47	74
SOUTH VANCOUVER ISLAND	181	1508	49	527
Total:	460	2283	176	781

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	44
NORTH VANCOUVER ISLAND	30
SOUTH VANCOUVER ISLAND	79
Total:	153

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	4	5	1
	35-49	16	18	11
	50+	19	24	11
	Total HSDA:	40	48	23
NORTH WEST	0-19	1	1	0
	20-34	9	13	8
	35-49	27	39	22
	50+	30	45	22
	Total HSDA:	67	98	52
NORTHERN INTERIOR	0-19	5	5	4
	20-34	27	30	18
	35-49	70	87	57
	50+	72	118	58
	Total HSDA:	174	240	137
Total HA:		281	386	212

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	4
	20-34	40	48	27
	35-49	113	144	90
	50+	121	187	91
Total HA:		281	386	212

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	176	245	135
Female	105	141	77

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	212	47	520	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	6
	5 years or more	11	7
	<5 years	14	10
	Total HSDA:	40	23
NORTH WEST	10 years or more	17	8
	5 years or more	23	21
	<5 years	27	23
	Total HSDA:	67	52
NORTHERN INTERIOR	10 years or more	51	34
	5 years or more	51	42
	<5 years	72	61
	Total HSDA:	174	137
Total HA:		281	212

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	83	48
	5 years or more	85	70
	<5 years	113	94
Total HA:		281	212

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	30	56	7	9
NORTH WEST	61	139	20	25
NORTHERN INTERIOR	97	380	24	181
Total:	188	575	51	215

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	5
NORTH WEST	20
NORTHERN INTERIOR	22
Total:	47

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	6
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	7
	THOMPSON/CARIBOO/SHUSWAP	19	34	18
	Total HA:	44	78	34
FRASER	FRASER EAST	31	39	24
	FRASER NORTH	62	91	47
	FRASER SOUTH	67	93	53
	Total HA:	160	223	124
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	41	19
	RICHMOND	8	13	7
	VANCOUVER	496	772	416
	Total HA:	526	826	442
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	48	73	37
	NORTH VANCOUVER ISLAND	13	22	10
	SOUTH VANCOUVER ISLAND	33	70	29
	Total HA:	94	165	76
NORTHERN	NORTH EAST	11	13	6
	NORTH WEST	33	56	28
	NORTHERN INTERIOR	63	95	58
	Total HA:	107	164	92
Total:		931	1456	768

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	591	938	475
Female	340	518	293

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	768	48	460	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.





Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.





Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).





PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a pill that contains DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Trimeq (TRQ): the ViiV Healthcare's trade name for a pill that contains DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a pill that contains ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a pill that contains TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

